Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

Abstract

Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN® in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life.

Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis

“…The patient had been priorly diagnosed with renal cell carcinoma in 1996 ( Sharan et al, 2020 ). Kumar et al. (2019) report a 63-year-old male who was diagnosed with prostate adenocarcinoma, which was at first organ confined and shifted to hormone-refractory metastatic disease 4 years post-initial diagnosis.…”

“…Post 6 months, the patient was additionally administered six booster shots over 6 months. Kumar et al (2019) presented a treatment history of 7 years, where personalized dendritic cell immunotherapy (APCEDEN) was commenced in the fourth-year post-diagnosis. APCEDEN was given in total over six doses, where the patient also received mitoxantrone to improve cell-mediated immunity ( Kumar et al, 2019 ).…”

“…The patient had been priorly diagnosed with renal cell carcinoma in 1996 (Sharan et al, 2020). Kumar et al (2019) report a 63-year-old male who was diagnosed with prostate adenocarcinoma, which was at first organ confined and shifted to hormone-refractory metastatic disease 4 years post-initial diagnosis. Karbach et al (2023) report a male patient in his 70s to report a patient with PCa case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1).…”

Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data

“…The 5-year survival rate of PRAD is about 70–100%; however, for patients with distant metastatic cancer, the 5-year survival rate is only 30% [ 3 ]. Among the most prevalent solid tumors with advanced disease, PRAD has the fewest therapeutic options, and advanced PRAD remains incurable [ 4 , 5 ]. Therefore, accurately evaluating the prognosis of PRAD is vital.…”

ZFC3H1 provides a reference to evaluate the prognosis and treat prostate adenocarcinoma: A study based on TCGA data

“…The 5-year survival rate of PRAD is about 70-100%; however, for patients with distant metastatic cancer, the 5-year survival rate is only 30% [3]. Among the most prevalent solid tumors with advanced disease, PRAD has the fewest therapeutic options, and advanced PRAD remains incurable [4,5].…”